Hey Thymus, sorry missed your reply here. I'll let the dust settle after today and get back to you with my general views. Sorry to see holders have to go through this again, it would seem that the EMA is still hanging on the manufacturing side of things, I'd be asking Q's along the lines of stability etc, this was from the last announcement:
It was evident from the detailed analysis of EMA questions when these were received earlier in 2014 that the most definitive response from Tissue Therapies would involve the development of additional test methods for stability and release for sale of VitroGro® ECM and that this would take a few months of work.
A detailed project plan for the development of this additional testing was reviewed and agreed in onsite meetings in Belgium with the Company’s key manufacturers, Eurogentec and Catalent during February 2014 and this has generated the data for the Company’s response to the EMA.
TIS Price at posting:
30.5¢ Sentiment: None Disclosure: Not Held
